Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient preference study of subcutaneous versus intravenous rituximab in previously untreated CD20-positive DLBCL or follicular lymphoma
2012-003230-17Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab and rituximab + hyaluronidase human in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Overall patient preference for rituximab administration route. Started Oct 2012; status: completed.
02
Drugs
rituximabrituximab + hyaluronidase human
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on 2012-003230-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003230-17.